48,845 Shares in Natera, Inc. $NTRA Bought by EFG International AG

EFG International AG purchased a new position in Natera, Inc. (NASDAQ:NTRA) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 48,845 shares of the medical research company’s stock, valued at approximately $13,263,000.

Several other institutional investors have also added to or reduced their stakes in the business. Trust Co. of Vermont purchased a new position in shares of Natera in the second quarter worth about $26,000. Reflection Asset Management purchased a new stake in Natera during the 4th quarter valued at about $29,000. Elevation Wealth Partners LLC purchased a new stake in Natera during the 2nd quarter valued at about $30,000. Palladiem LLC bought a new position in Natera during the 4th quarter worth approximately $31,000. Finally, Horizon Investments LLC bought a new position in Natera during the 3rd quarter worth approximately $32,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on NTRA. Morgan Stanley reiterated an “overweight” rating and issued a $355.00 price objective on shares of Natera in a research report on Monday, August 10th. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. TD Cowen lifted their target price on shares of Natera from $325.00 to $340.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Wall Street Zen downgraded shares of Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, UBS Group set a $260.00 price target on shares of Natera in a report on Wednesday, June 24th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and a consensus price target of $319.38.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $336.71 on Wednesday. The stock’s 50-day moving average is $278.79 and its 200 day moving average is $231.01. The company has a market cap of $48.53 billion, a PE ratio of -247.58 and a beta of 1.51. Natera, Inc. has a 1 year low of $157.43 and a 1 year high of $337.12.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The business’s revenue was up 37.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.74) EPS. Analysts expect that Natera, Inc. will post -1.02 EPS for the current fiscal year.

Insider Activity at Natera

In related news, Director Gail Boxer Marcus sold 11,000 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the completion of the transaction, the director owned 6,183 shares in the company, valued at $1,343,009.43. This represents a 64.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Solomon Moshkevich sold 3,410 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $265.58, for a total value of $905,627.80. Following the completion of the sale, the insider directly owned 129,019 shares of the company’s stock, valued at $34,264,866.02. The trade was a 2.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 177,955 shares of company stock valued at $40,704,193 over the last 90 days. Company insiders own 5.05% of the company’s stock.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.